Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors.
Gould, A.E., Adams, R., Adhikari, S., Aertgeerts, K., Afroze, R., Blackburn, C., Calderwood, E.F., Chau, R., Chouitar, J., Duffey, M.O., England, D.B., Farrer, C., Forsyth, N., Garcia, K., Gaulin, J., Greenspan, P.D., Guo, R., Harrison, S.J., Huang, S.C., Iartchouk, N., Janowick, D., Kim, M.S., Kulkarni, B., Langston, S.P., Liu, J.X., Ma, L.T., Menon, S., Mizutani, H., Paske, E., Renou, C.C., Rezaei, M., Rowland, R.S., Sintchak, M.D., Smith, M.D., Stroud, S.G., Tregay, M., Tian, Y., Veiby, O.P., Vos, T.J., Vyskocil, S., Williams, J., Xu, T., Yang, J.J., Yano, J., Zeng, H., Zhang, D.M., Zhang, Q., Galvin, K.M.
J.Med.Chem.
